SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Regeneron Pharmaceuticals -- Ignore unavailable to you. Want to Upgrade?

To: DewDiligence_on_SI who wrote (2248)1/16/2018 1:36:26 PM
From: Miljenko Zuanic  Read Replies (1) | Respond to of 3559
 
Will see how long it will take them to emend protocol? REGN is in control of the trial (REGN control 2810), so I hope that they have common sense (regardless JY scientific-EGO), but than again my HOPE may be MISPLACED!



To: DewDiligence_on_SI who wrote (2248)1/25/2018 2:48:29 PM
From: Miljenko Zuanic  Read Replies (2) | Respond to of 3559
 
They are incorporating anti-CTLA4 with 2810 as well, for L1 NSCLC, good for BMY.

clinicaltrials.gov

Maybe their exomes profiling of the cancers samples point toward this combination, or they simple bet where lider lead???

They have their own anti-CTLA4 antibody (in preclinical).


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News